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Abstract 
 
Background: The precise mechanisms controlling homing of T effector (Teff) cells to 
the inflamed gut in Crohn’s disease (CD) are still unclear and clinical outcome data 
from inflammatory bowel disease (IBD) patients treated with the anti-α4β7 integrin 
antibody vedolizumab suggest differences between ulcerative colitis (UC) and CD. 
Methods: Expression of homing molecules was studied with flow cytometry and 
immunohistochemistry. Their functional role was investigated in in vitro adhesion 
assays and in a humanized mouse model of T cell homing to the inflamed gut in vivo. 
Results: Despite in vitro blockade of CD Teff adhesion to MAdCAM-1 and in contrast 
to previous oberservations in UC, anti-α4β7 treatment did not result in reduced Teff 
cell homing to the gut in vivo. However, the integrin α4β1 was expressed in higher 
levels on Teffs from CD patients compared with controls, while its expression in the 
peripheral blood declined and its expression in the intestine increased during the 
course of clinical vedolizumab treatment. Consistently, adhesion of CD Teffs to 
VCAM-1 was blocked by inhibition of α4 and α4β1 in vitro. Moreover, in vivo homing 
of CD Teffs to the inflamed ileum was reduced by inhibition of α4 and α4β1 integrins, 
but not α4β7 integrins.  
Conclusions: Our findings suggest that Teff cell homing to the ileum via the axis α4β1 
– VCAM-1 is an essential and non-redundant pathway in CD in vivo possibly affecting 
efficacy of clinical treatment with anti-adhesion compounds. 
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Introduction 
 
The pathogenesis of inflammatory bowel diseases (IBD) such as Crohn’s disease 
(CD) and ulcerative colitis (UC) remains poorly understood. However, a crucial role of 
the immune system in the initiation and perpetuation of chronic intestinal 
inflammation is beyond question1–3.  
Lymphocyte homing from postcapillary high endothelial venules to the inflamed gut 
contributes to amplification of intestinal effector T lymphocyte (Teff) populations that 
outnumber increased regulatory T cells (Tregs)4. Subsequently, augmented cytokine 
signaling in effector T cells leads to further immune cell activation resulting in 
damage of intestinal structures and clinical symptoms like diarrhea, bleeding or pain5.  
Homing to the inflamed intestine is a tightly regulated multistep process that has only 
been rudimentarily uncovered. In general, lymphocytes establish contact with and roll 
along the endothelium through interaction of selectins with selectin ligands. This is 
followed by chemokine-induced cell activation and promotes firm adhesion to the 
endothelium by binding of integrins to respective addressins. Subsequently, 
lymphocytes may cross the endothelial wall by migrating para- or transcellularly to 
the lamina propria6. In the intestine, interaction of α4β7 integrin with mucosal 
vascular addressin cell adhesion molecule (MAdCAM)-1 is an important and gut-
specific homing mechanism7. Consequently, therapeutic blockade of α4β7 by the 
monoclonal antibody vedolizumab that was developed from the mouse anti-human 
α4β7 antibody Act-18 is successfully used for clinical treatment of patients with both 
UC and CD9,10. Additionally, adhesion of α4β1 to vascular cell adhesion molecule 
(VCAM)-1 has been identified as an important mechanism for gut homing of 
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lymphocytes but successful therapeutic inhibition with the anti-α4 antibody 
natalizumab11 was abandoned due to severe cerebral viral infections probably 
resulting from concurrent blockade of lymphocyte homing to the central nervous 
system12. 
We have recently shown that vedolizumab decreases colonic homing of UC Teffs in a 
humanized mouse model in vivo and that CD Teff cells express α4β7 similarly to UC 
Teff cells13. However, the functional implications for in vivo homing of Teff cells from 
CD patients have not yet been addressed. Moreover, clinical data suggest that 
vedolizumab might be more beneficial in UC than in CD14 but a molecular 
explanation is missing. 
In the present study, we demonstrate that inhibition of α4β7-dependent homing of Teff 
cells from CD may be bypassed by compensatory homing to the ileum via α4β1 
integrin in a humanized mouse model in vivo. Our data indicate that due to an 
essential role of the α4β1 integrin/VCAM-1 pathway for gut homing in CD, therapeutic 
interference with α4β7 integrin might now work as well in this disease. 
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Materials and Methods: 
 
IBD patients 
Following informed written consent peripheral blood and gut samples from patients 
with CD (n = 116) and UC (n = 39) were collected according to the regulations of the 
local Ethics Committee at the Medical Clinic I of the University Hospital Erlangen. 
Controls (n = 49) came from blood and tissue specimens provided by healthy donors 
and tumor patients, respectively. IBD gut samples were from areas of active disease. 
Patients receiving vedolizumab were recruited during the induction phase of 
treatment and followed up for 14 +/- 0.5 weaks with periodic collection of blood 
samples.  
 
Immunohistochemistry 
Cryopreserved tissue sections were fixed in 4 % paraformaldehyde and sequentially 
blocked with avidin/biotin blocking reagent (Vector Laboratories) and protein-blocking 
reagent (Roth). Primary antibodies specific for CD4 (RPA-T4, BD), α4 integrin (D2E1, 
Cell Signaling), β1 integrin (JB1B, Abcam), α4β7 integrin (Vedolizumab, Takeda), α4 
integrin (Natalizumab, Biogen) and CCR2 (polyclonal, Abcam) were used. The slides 
were subsequently incubated with fluorescent- or biotin-labeled secondary antibodies 
(Vectorlabs and Merck) followed by treatment with Dylight488- or Cy3-conjugated 
streptavidin (Biolegend), if applicable. Natalizumab was directly labelled with Alexa 
Fluor 647 (Thermo Fisher). Nuclei were counterstained with Hoechst reagent 
(molecular probes) and samples were analyzed by fluorescence and confocal 
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microscopy (DMI6000B and LSM SP8, Leica). Single and double positive cells in at 
least three high power fields were counted.  
 
Cell isolation and in vitro treatment 
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient 
centrifugation with Pancoll (Pan Biotech). CD4+CD25- Teff cells were isolated using 
the CD4+CD25+ Treg isolation kit (Miltenyi Biotec) according to the manufacturer’s 
instruction. Where indicated, cells were cultured in RPMI 1640 medium (Gibco) with 
10 % FCS (Pan Biotech) and 1 % penicillin/streptomycin (Biochrom) and treated with 
vedolizumab (Takeda) and natalizumab (Biogen) at the indicated concentrations. 
 
Flow cytometry 
For flow cytometric analyses, human cells were incubated with antibodies against 
CD4 (VioBlue, VIT4, Miltenyi Biotec), CCR2 (BV605, K036C2, Biolegend), α4-integrin 
(FITC, MZ18-24A9, Miltenyi Biotec), β7-integrin (PerCP/Cy5.5, FIB27, Biolegend), 
ß1-integrin (AF647, TS2/16, Biolegend) or FoxP3 (PE, 236A/E7, eBioscience). For 
intracellular staining, cells were treated with the Foxp3/Transcription Factor Staining 
Buffer Set (eBioscience). Analyses were performed on an LSR Fortessa instrument 
(BD).  
 
MAdCAM-1/VCAM-1 adhesion assay 
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Adhesion assays were performed on epoxy-coated glass slides (Neolab) as 
previously described13,15. Wells were coated with Fc chimera of rhMAdCAM-1 and 
rhVCAM-1 (both 5 µg/mL, both from R&D) in 150 mM NaCl with 20 mM HEPES 
(AMRESCO) at 37 °C overnight followed by blocking with 5 % BSA at 37 °C for two 
hours. 200,000 cells (purified CD4+ or CD4+CD25- cells as indicated) in adhesion 
buffer were added for 90 minutes at 37 °C. After washing, adherent cells were 
counterstained with Hoechst and slides were analyzed by fluorescence and confocal 
microscopy. In blocking experiments, cells were treated with the indicated 
concentrations of vedolizumab and natalizumab or 100nM or the small molecule 
α4β1 inhibitor BIO5192 (Tocris Bioscience). 
 
Dynamic VCAM-1 adhesion assay 
Ultra-thin glas capillaries (Vitrocom) were coated with Fc chimera of rhVCAM-1 (5 
µg/ml) and subsequently blocked with 5 % BSA, one hour at 37° C each. Cells were 
labeled with CFSE (Life technologies) and treated as mentioned above. The glass 
capillaries were connected with plastic tubings and suspensions of 1.5 million cells/ml 
were perfused through the capillaries at a rate of 2.0ml/h by a perfusion pump (B. 
Braun). Analyses were performed by taking clips of 3 minutes length with time-lapse 
confocal microscopy. For quantification three sequential images at the beginning and 
the end of these 3 minutes were exported, colored in red, green and blue and 
subsequently merged in ImageJ. In the composite image, stationary cells appeared 
white while moving cells kept the assigned color. White cells at the beginning and the 
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end of the sequences were counted with and the difference (i.e. number of adhering 
cells in 3 minutes) was calculated. 
 
Humanized mouse model of in vivo homing to the inflamed gut 
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) and RAG1-deficient (B6 RAG1-/-) mice 
lacking native lymphocytes were housed in individually-ventilated cages. Dextran 
sodium sulfate (DSS) colitis and adoptive transfer experiments were performed as 
recently described13. Briefly, two million Teff cells were labeled with CFSE and 
treated with 100 µg/mL vedolizumab or 100 µg/mL natalizumab overnight, where 
specified. Where indicated, mice were injected with 0.5mg of the α4β1 inhibitor 
BIO5192 12h prior to adoptive transfer of cells. Mice were anesthetized with 
ketamine/xylazine by intraperitoneal injection. Subsequently, Hoechst dye was 
injected to the tail vein for murine cell staining. CFSE-labeled cells and Texas Red 
Dextran (Life technologies) for vessel staining were injected into the ileocolic artery 
guided by a stereomicroscope (Leica). For in vivo imaging, the colon was 
longitudinally opened and the mucosa positioned on a glass transparent petri dish 
prior to intravital analysis with an SP8 confocal microscope (Leica).  
For flow cytometric analyses, mice were sacrificed one hour after adoptive transfer 
and T cell enriched lamina propria mononuclear cells (LPMCs) were isolated using 
the lamina propria isolation kit (Miltenyi Biotec). The CFSE+ fraction was quantified by 
flow cytometry.  
 
Statistics 
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Statistical differences were identified using ANOVA or student’s t-test where 
applicable in Graph Pad Prism (Graph Pad Software). Levels of significance are 
indicated by asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001). Graphs display means 
with SEM indicated by error bars.  
 
Ethical considerations 
Patient material was obtained after informed written consent and according to the 
regulations and approval of the Ethics Committee of the University Erlangen-
Nuremberg. Mice were housed and cared for according to the Guidelines for the Care 
and Use of Laboratory Animals and experiment were performed according to the 
approval of the Government of Lower Franconia. 
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Results 
 
Vedolizumab blocks adhesion of CD Teff cells to MAdCAM-1 in vitro but does 
not reduce CD Teff cell homing to the inflamed colon in vivo 
Recent data from our group have shown that binding of Teff cells from UC patients to 
MAdCAM-1 is blocked by vedolizumab in vitro and that vedolizumab treatment 
results in reduced in vivo Teff homing to the inflamed gut in a humanized mouse 
model13. However, the question whether similar observations can be made in Teff 
cells from CD patients remained unclear. We therefore set out to explore these 
interactions in CD. As expected, vedolizumab inhibited in vitro adhesion of overall 
blood CD4+ T cells and CD4+CD25- Teff cells from both CD patients and controls to 
MAdCAM-1 coated glass slides, although effects in CD were not clearly dose-
dependent (Suppl. Fig. 1, Fig. 1A). Next, we investigated α4β7 inhibition of CD Teff 
cells by vedolizumab in the aforementioned humanized mouse, model in which 
human T cells are injected into the ileocolic artery of immunodeficient colitic mice. 
Colitis was induced with DSS prior to injection of CFSE labeled CD Teff cells and 
fluorescence dyes as described in the methods section.  
By means of intravital confocal microscopy human CD lymphocytes that had homed 
to the colonic lamina propria could be observed. Unexpectedly and in contrast to our 
previous observations in UC13, however, no significant difference between untreated 
and vedolizumab-treated CD Teff cells was noticed microscopically or upon flow 
cytometric analysis of CFSE+ human cells within the LPMCs from the murine colon 
(Fig. 1B).  
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This was mirrored by the finding that unlike in UC13 the ratio of effector CD4+Foxp3- 
and regulatory CD4+Foxp3+ T cells in the peripheral blood of CD patients receiving 
vedolizumab did not change over the course of therapy (Suppl. Fig. 1B). Taken 
together, these data suggested that in spite of efficient blockade of α4β7-mediated 
Teff cell adhesion to MAdCAM-1 and although CD and UC Teffs express similar 
levels of α4β713, homing via α4β7 might be less functionally relevant for colonic in 
vivo homing of CD Teff cells to the inflamed gut in our humanized mouse model 
compared with UC Teff cells.  
 
Increased expression of α4β1 on peripheral and intestinal Teff cells from CD 
patients and reciprocal regulation of peripheral and intestinal α4β1 expression 
under vedolizumab therapy 
We reasoned that this finding could be due to a preferential or compensatory use of 
alternative homing pathways by CD Teff cells. Accordingly, we analyzed the 
expression of various alternative homing markers on Teff cells in the peripheral blood 
of CD patients. While we detected no differences in the expression of several homing 
markers like CD62L or PSGL-1 (Suppl. Fig. 2A), we found that the number of 
α4+β1high Teff cells was significantly increased in CD compared with UC and controls. 
Similarly, more peripheral CCR2+ Teff cells were found in CD as compared to control 
patients (Fig. 2A). 
We therefore further addressed these markers and assessed their intestinal 
expression by immunohistochemistry. Matching with higher expression in the 
peripheral blood the number of α4+β1+ and CD4+CCR2+ cells was significantly higher 
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in cryosections from inflamed CD compared with inflamed UC and control patients 
(Fig. 2B, Suppl. Fig. 2B). 
To explore whether these molecules might be a potential bypass of α4β7-dependent 
homing, we measured the expression of α4β1 and CCR2 in CD patients receiving 
clinical vedolizumab therapy. While CCR2 levels did not significantly change over the 
course of 14 weeks, we discovered that expression of α4β1 distinctly declined over 
the observed course in almost all CD but not UC patients (Fig. 2C). This might be 
explained by peripheral contraction of α4β1-expressing cells in favor of 
compensatory enrichment in the intestinal lamina propria in CD, when α4β7-
dependent homing is blocked. On the contrary, upregulation of CCR2 in CD patients 
does not seem to result in counter-regulatory increased CCR2-dependent homing in 
vedolizumab patients. Consistently, stainings of cryosections from biopsies of CD 
patients undergoing colonoscopy directly prior to initiation of therapy with 
vedolizumab or follow-up colonoscopy during the maintenance phase of vedolizumab 
treatment indicated that the number of α4β1-positive cells was increased in the latter 
group (Fig. 2D, Suppl. Fig. 2C). Moreover, we found that a significant portion of 
α4β7+ cells co-expresses α4β1 (Suppl. Fig. 2D). As this was consistent with the idea 
that vedolizumab-induced blockade of the α4β7 homing pathway might be 
circumvented by the α4β1 pathway, we focused on α4β1 and its ligand VCAM-1 in 
further steps.  
 
Preferential ileal homing of CD Teff cells 
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Besides homing via alternative pathways we also considered that regarding the 
clinical distribution of CD it might be additionally relevant to study ileal homing with 
CD Teff cells. Accordingly, we determined ileal homing of Teff cells in vivo in our 
mouse model. First, we assessed the expression of VCAM-1, the receptor for α4β1 in 
the ileum of the DSS treated mice used in our study by performing 
immunohistochemistry on ileal cryosections from DSS treated and untreated mice. 
We found that while expression in non-inflamed tissue was low, it was markedly 
upregulated in the ileum of DSS treated mice (Fig. 3A). Thus, although macroscopic 
signs of ileal inflammation are largely absent upon DSS treatment, this finding added 
to earlier reports fueling the notion that some features of inflammation extend beyond 
the colon to the ileum16–18 and, more specifically, suggested that our model is valid 
for the investigation of α4β1-dependent ileal homing as it served to induce the 
necessary ligand in the ileum. Moreover, upon adoptive transfer of untreated Teff 
cells from CD patients to the ileocolic artery of DSS-treated mice, intravital confocal 
microscopy demonstrated homed T cells in ileal villi (Fig. 3B), similarly supporting the 
applicability of our model for the exploration of in vivo homing to the ileum. 
Next, we compared colonic and ileal homing after adoptive transfer of untreated CD 
Teff cells. We observed high amounts of human CD Teff cells in the murine ileum by 
in vivo microscopy, while colonic numbers were markedly lower (Fig. 3C). 
Quantification by flow cytometry of lamina propria mononuclear cells (LPMCs) 
isolated from the mice confirmed this observation, since a significant difference was 
noted between ileal and colonic CD Teff cell infiltrates. This difference was more 
pronounced in CD patients with small intestinal involvement (L1 and L3 phenotypes 
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according to the Montreal classification) than in patients without ileal involvement (L2 
phenotype) (Suppl. Fig. 3). 
To exclude that this was an effect related to our in vivo model, we performed similar 
experiments with untreated cells from healthy control donors. Here, colonic and ileal 
cell accumulation were not significantly different but tended towards higher colonic 
levels (Fig. 3D). This suggested that the effects seen with CD Teff cells were specific 
for the disease.  
This was consistent with the notion that unaffected colonic homing of CD Teff cells 
upon vedolizumab treatment in our humanized mouse model might be explained not 
only by alternative homing via α4β1 and VCAM-1 but also by a predominant role of 
ileal homing in CD. 
 
Static and dynamic adhesion to VCAM-1 is blocked by natalizumab 
Hence, we decided to study adhesion of α4β1 to VCAM-1 more closely. VCAM-1-
coated glass slides where incubated with Teff cells from CD patients that had been 
treated with different concentrations of vedolizumab and natalizumab in vitro (Fig. 4A, 
C). As expected, the anti-α4 antibody natalizumab dose-dependently reduced 
adherence of Teff cells to VCAM-1, while vedolizumab had a significant effect only at 
non-physiologically relevant concentrations19 matching with previous data that report 
some binding of α4β7 to VCAM-1 as well20,21. 
However, these experiments only addressed static adhesion and might therefore not 
fully reflect the physiological situation where adhesion happens under the dynamic 
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flow conditions of the blood stream with shear stress. Thus, we refined our technique 
to investigate adhesion to VCAM-1 under flow by perfusing VCAM-1 coated ultra-thin 
glass capillaries with suspensions of CD Teff cells (Fig. 4B, Suppl. Video 1).  
While virtually no cells adhered to uncoated glass capillaries, many untreated cells 
bound to VCAM-1-coated counterparts. Fitting to the observations under static 
conditions, adhesion of natalizumab treated cells was obviously and significantly 
reduced, while vedolizumab had no significant effect (Fig. 4C). 
 
Pan-α4 but not α4β7 inhibition blocks ileal homing of CD Teff cells in vivo 
Consequently, we compared the implications of α4β7 and α4 blockade for ileal 
homing in our humanized mouse model and transferred vedolizumab and 
natalizumab treated Teff cells from CD (Fig. 5A). Quantitative analyses revealed that 
while vedolizumab only had a marginal effect that missed statistical significance, 
natalizumab significantly reduced ileal numbers of CD Teff cells (Fig. 5B).  
As natalizumab additionally blocks α4β1, this further supports the concept that this 
molecule might be essential in CD to explain our findings for α4β7.  
 
Inhibition of α4β1 but not α4β7 blocks ileal homing of CD Teff cells in vivo 
However, since natalizumab is a pan-α4 inhibitor these experiments were not 
suitable to directly address the role of α4β1. Thus, we performed experiments using 
the specific α4β1 inhibitor BIO5192.  
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In vitro adhesion assays demonstrated that this inhibitor reduces adherence of CD 
Teff cells to VCAM-1 to a level comparable with natalizumab (Fig. 6A). In our 
humanized mouse model, α4β1 inhibition with or without vedolizumab significantly 
reduced in vivo homing to the inflamed ileum, while vedolizumab alone again failed to 
induce a significant effect (Figs. 6B, C). 
Taken together, these findings suggested that blockade of α4β1 might be sufficient to 
impede homing of CD Teff cells to the inflamed ileum while inhibition of α4β7 – 
though preventing adhesion to MAdCAM-1 – might be compensated by increased 
homing via α4β1. 
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Discussion 
 
Although the precise role of intestinal T lymphocyte trafficking in IBD is still 
incompletely understood, both recent data from basic and translational research and 
clinical advances have underscored the importance of this process in the framework 
of chronic intestinal inflammation22–25. After the episode of natalizumab, which was 
effective in CD but led to serious safety concerns12,26, this has finally been clinically 
implemented by the monoclonal anti-α4β7 integrin antibody vedolizumab.  
The efficacy of vedolizumab in both UC and CD has been demonstrated in several 
trials9,10 and no increased risk for infections of other organs has been reported so 
far27, thus supporting the concept of gut-specific inhibition of homing by this 
molecule7,22. However, clinical observations also suggest that gut homing might be of 
differential relevance and might be differentially controlled in UC and CD as the main 
entities of IBD. In concrete terms, while it is beyond question that vedolizumab is 
effective in both diseases, several studies indicate that vedolizumab might be 
beneficial for a higher percentage of UC than CD patients or have a faster time to 
response in UC28. In the GEMINI 2 phase III induction trial, a significantly higher 
proportion of CD patients receiving vedolizumab had a clinical remission compared 
with patients receiving placebo, but no significant effect was observed in the CDAI-
100 response or in the change of CRP levels. In the maintenance study, higher rates 
of clinical remission and response compared with placebo were reported, yet, these 
differences only appeared very late in the one-year course of therapy and rates of 
durable clinical remission were similar10. In the GEMINI 3 trial, moreover, differences 
in clinical remission were only detectable at week ten but not at week 629. On the 
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contrary, vedolizumab met all primary endpoints in the UC GEMINI 1 induction trial, 
i.e. clinical remission, clinical response and mucosal healing. Moreover, it induced 
significantly higher rates of remission, response, mucosal healing, steroid-free and 
durable remission in the maintenance phase9. Although some open-label studies 
reported similar efficacy in both diseases30,31 later reports indicated higher 
percentages for remission, response and mucosal healing in UC compared with 
CD32,33 matching with our own clinical experience, and two recent meta-analyses 
found higher RR values for remission and response endpoints in UC than in CD14,34.  
To date, the reason for these differences is not clear. We have recently introduced a 
humanized mouse model taking advantage of DSS-treated immunodeficient mice to 
study vedolizumab effects on homing of T lymphocytes from UC patients13,35. Using 
this model we now addressed colonic and ileal homing of CD effector T lymphocytes 
and reveal that redundant homing via α4β1 might be an explanation for the above 
mentioned observations. 
While our first experiments confirmed that vedolizumab blocks α4β7-mediated 
adhesion to MAdCAM-1 in T lymphocytes from CD similarly to UC, we were 
astonished that we were not able to detect a significant effect in our humanized 
mouse model of homing to the inflamed colon. Compared with our previous data on 
UC, we only observed a modest decrease in colonic lymphocyte accumulation upon 
treatment with vedolizumab that did not reach statistical significance. We had also 
shown that the peripheral Treg population increases within the first weeks of 
vedolizumab treatment in UC patients resulting in a decreasing Teff/Treg ratio, which 
potentially leads to suppression of systemic inflammation13. Similar analyses in CD 
patients treated with vedolizumab at our department did not show any change in the 
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ratio for Foxp3-/Foxp+ CD4 T cells in the same period of time, thus further supporting 
the notion that effects of α4β7 inhibition are not identical in CD and UC. The 
mechanistic consequence of this finding remains an object of speculation as it is not 
clear to what extent intestinal Treg and Teff pools and their imbalance in IBD depend 
on homing from the bloodstream and local induction or proliferation in the 
intestine4,36. However, it underscores differences in α4β7-mediated homing and 
therapeutic α4β7 blockade between UC and CD. 
We considered three potential approaches towards an explanation for our in vivo 
findings of only non-significant vedolizumab effects:  
First, lack of α4β7-dependent homing of CD Teff cells in our system. However, 
regarding the clear effect of vedolizumab on CD T lymphocytes in vitro, the 
previously observed effects of vedolizumab on UC T cell homing, the expression of 
murine MAdCAM-1 in DSS-treated immunodeficient mice and the ability of human 
α4β7 to bind to murine MAdCAM-113 it was very unlikely that vedoliumab would not 
inhibit interaction of α4β7 with MAdCAM-1 and thus α4β7-dependent homing in our 
humanized in vivo model.  
Second, compensatory homing via alternative receptors, i.e. a partly redundant role 
of α4β7 in CD. Consequently, we analyzed the expression of alternative homing 
markers on Teff lymphocytes and, in fact, we found a significant upregulation of α4β1 
and CCR2 in the peripheral blood and the gut in CD but not in UC compared with 
controls. Sequential measurements of α4β1 on Teff cells from CD patients treated 
with vedolizumab revealed a reduction of the peripheral expression in the course of 
treatment, while – reciprocally – immunohistochemistry of gut tissue suggested an 
intestinal increase. This was indeed compatible with a compensatory shift of α4β1+ 
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Teff cells from the peripheral blood to the diseased intestine. A similar concept has 
earlier been established in a murine model of chronic ileitis, where single blockade of 
neither α4β7 nor MAdCAM-1 resulted in disease protection. However, the authors 
could show that the combination of MAdCAM-1 and L-Selectin inhibition reduced 
disease severity and as α4β1 and α4β7 were frequently co-expressed they proposed 
that interference with one of these pathways might result in alternative homing via the 
other one37. An earlier report from the same group pointed in a similar direction. 
Here, single blockade of the addressins ICAM-1, VCAM-1 or the integrin α4 had no 
effect on murine ileitis, while dual inhibition of ICAM-1 with VCAM-1 or α4 reduced 
colitis severity38. In this context, it is also interesting to mention that alicaforsen, an 
antisense inhibitor of ICAM-1 did not show efficacy in CD, which might also be 
explained by redundant homing pathways39. 
Third, an only minor role of colonic homing in CD compared with UC. Addressing this 
possibility, we compared ileal and colonic homing of CD Teff lymphocytes and found 
that more of these cells homed to the ileum than to the colon. Given the prevalent 
disease distribution3 this seems not very surprising and, thus, we decided to study 
α4β1- and α4β7-dependent homing of cells from CD patients to the murine ileum.  
In these experiments, we could demonstrate that – again – α4β7 inhibition through 
vedolizumab caused a non-significant minor decrease in homing, while blockade of 
α4 with natalizumab and thus α4β7 in combination with α4β1 resulted in a marked 
reduction of homing. This was consistent with compensatory α4β1-dependent 
homing in the presence of anti-α4β7 treatment. However, it did not answer the 
question whether α4β7 might also work as an alternative pathway bypassing α4β1 
blockade. We thus treated mice with an α4β1 inhibitor and compared the effects to 
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vedolizumab. Both α4β1 inhibitor alone and in combination with vedolizumab resulted 
in a significant decrease of homed cells compared to no treatment or only 
vedolizumab treatment. This observation favors the idea that while α4β7 blockade 
can be circumvented by α4β1-dependent homing, α4β1 is essential for ileal homing 
of Teff cells in CD and its blockade cannot be evaded by compensatory use of the 
α4β7 pathway (Fig. 7).  
It is not finally clear, why this seems to be clinically relevant in CD but not in UC. 
While one reason might be the higher expression of α4β1 in CD, another possibility is 
that α4β7 circumvention by α4β1 is not a specific feature of homing in CD but rather 
a feature of ileal compared with colonic homing. Another issue in this context might 
be time. As mentioned above, significant effects of vedolizumab in CD were more 
likely to be observed at later time points in clinical trials10,29. Naturally, our model only 
examines short-term trafficking and is therefore not able to reveal long-term effects of 
the drugs tested. Thus, it is possible that vedolizumab exerts its effect in CD by 
constantly leading to slight reductions in homing that have to accumulate over time 
before active inflammation is measurably suppressed. Apart from this and regarding 
our data it seems essential to place effort in the identification of suitable biomarkers 
to predict the individual response to vedolizumab therapy like it was conceptually 
shown for adalimumab or etrolizumab24,40.  
Taken together, our data show for the first time that human Teff cells may circumvent 
inhibition of one integrin by homing to the inflamed gut via another one in vivo and 
thereby evade targeted anti-integrin therapy. These findings emphasize the need for 
refinement of current and development of future therapies interfering with intestinal 
trafficking.
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Figure legends: 
 
Figure 1: Homing of CD Teff cells to the inflamed murine colon is not 
significantly affected by vedolizumab 
(a) Adhesion of control and CD Teff cells to MAdCAM-1-coated glass slides. Left 
panels: Representative adhesion assays showing adhered cells from control and CD 
upon treatment with different concentrations of vedolizumab as indicated. Right 
panels: Pooled statistics (n = 5-7).  
(b) In vivo homing of CD Teff cells to the inflamed colon. Left panels: Representative 
intravital microscopy of the murine colon upon adoptive transfer of human cells. 
Green: human cells (→), red: murine vessels, blue: murine cells. Right upper panels: 
Representative flow cytometry displaying the relative proportion of colonic CFSE+ 
human cells in a control mouse without transfer and mice after transfer of CD Teff 
cells treated with or without vedolizumab. Right lower panels: Pooled statistics (n = 
13). 
 
Figure 2: Increased expression of α4β1 in CD patients and reciprocal peripheral 
vs. intestinal regulation under vedolizumab therapy 
(a) Flow cytometric analyses of α4β1 and CCR2 expression on peripheral 
CD4+CD25- Teff cells in controls (n = 20), CD (n = 31) and UC (n = 9). Left upper 
panels: Representative plots showing the percentage of α4+β1high cells. Left lower 
panels: Representative plots showing the percentage of CCR2+ cells. Right upper 
panel: Quantitative analysis and statistics of α4+β1high Teff cells in controls, CD and 
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UC. Right lower panel: Quantitative analysis and statistics of CCR2+ T eff cells in 
controls, CD and UC. 
(b) Immunohistochemistry of α4β1 (left) and CCR2 (right) expression in the human 
intestine in controls (n = 5-7), CD (n = 6-7) and UC (n = 3-7). Left upper panels: 
Representative stainings of α4 and β1. Right upper panels: Representative stainings 
of CD4 and CCR2. Scale bars: 25µm. Left lower panels: Quantification and statistical 
analysis of the number of α4β1-double positive cells in controls, CD and UC. Right 
lower panels: Statistical analysis of the number of CD4+CCR2+ cells in controls, CD 
and UC. 
(c) Relative peripheral α4β1 and CCR2 expression on Teff cells over the course of 
Vedolizumab therapy. Peripheral blood form CD (left panels, n = 8) and UC patients 
(right panels, n = 6) receiving vedolizumab was analyzed by flow cytometry for α4β1 
and CCR2 expression at recruitment and after 14 +/- 0.5 weaks. Values were 
normalized to the first value. 
(d) Immunohistochemistry of α4β1 expression in the intestine of CD patients directly 
prior to vedolizumab therapy (n = 4) and during the maintenance phase of treatment 
(n = 5). Slides were stained with vedolizumab and natalizumab and single 
natalizumab-positive cells were considered α4β1+. BT – before therapy, MP – 
maintenance phase. 
 
Figure 3: CD Teff cells preferentially home to the ileum of humanized mice in 
vivo 
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(a) Immunohistochemistry of VCAM-1 in ileal cryosections from mice treated with 
DSS or not. Representative images from one out of three independent experiments 
are shown. Scale bars: 25µm. 
 (b) Representative images of intravital confocal microscopy from the murine ileum 
after adoptive transfer of CD4+CD25- T cells from CD patients. Scale bars: 100µm 
and 25µm (inserts). 
(c) Left upper panels: Representative flow cytometry plots comparing ileal and 
colonic accumulation of CD Teff cells. Left lower panels: Quantitative flow cytometry 
of CFSE+ cells from CD patients the ileal and colonic lamina propria of DSS treated 
mice after adoptive transfer (n = 10). Right panels: Representative images of in vivo 
microscopy comparing CD Teff cell homing to the inflamed ileum and colon as 
indicated. Scale bars: 75µm and 25µm (inserts). Green: CFSE (→), red: Texas Red 
Dextran, blue: Hoechst. 
d) Quantitative flow cytometry of CFSE+ cells from control donors in the ileal and 
colonic lamina propria of DSS treated mice after adoptive transfer (n = 7). 
 
Figure 4: Static and dynamic adhesion to VCAM-1 
(a) Adhesion of CD Teff cells to VCAM-1 coated glass slides. Representative 
adhesion assays showing adhesion to VCAM-1 upon treatment with different 
concentrations of vedolizumab (VDZ) and natalizumab (NTZ) as indicated. Scale 
bars: 50µm and 25µm (inserts).  
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(b) Dynamic adhesion of CFSE-labeled CD Teff cells to VCAM-1 coated glass 
capillaries perfused with a perfusion pump. Representative sequential images at the 
indicated relative time points. Coating of the capillary and treatment of the cells is 
specified on the left. White circles connected by white lines highlight positions where 
cells newly adhere to the capillary, red circles connected by red lines show positions 
where cells pass the field of view without adhering. Also cf. Suppl. Video 1.  
(c) Quantification of adhesion assays. Left panel: Pooled statistics (n = 5) of static 
adhesion assays showing the number of cells adherent to VCAM-1-coated glass 
slides. Right panel: Pooled statistics (n = 3) of dynamic adhesion assays showing the 
number of cells adhering to VCAM-1 over three minutes. Values were normalized to 
untreated cells. 
 
Figure 5: Pan-α4 but not α4β7 inhibition impedes ileal homing of CD Teff cells 
in vivo 
(a) Representative intravital confocal microscopy upon transfer of CD4+CD25- cells 
from CD and treatment as indicated. Green: human cells (→), red: murine vessels, 
blue: murine cells. Scale bars: 100µm and 25µm (inserts). 
(b) Flow cytometric quantification of ileal homing upon treatment with natalizumab 
(NTZ) and vedolizumab (VDZ). Left panels: Representative plots. Right panels: 
Pooled statistics (n = 5). 
 
Figure 6: α4β1 inhibition is essential for ileal homing of CD Teff cells in vivo 
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(a) Adhesion of CD Teff cells to VCAM-1 coated glass slides. Left panels: 
Representative adhesion assays showing adhesion to VCAM-1 upon treatment with 
different concentrations of natalizumab (NTZ) or α4β1 inhibitor as indicated. Scale 
bars: 50µm and 25µm (inserts). Right panels: Pooled statistics (n = 5). 
(b) Representative intravital confocal microscopy upon transfer of CD4+CD25- cells 
from CD and treatment as indicated. Green: human cells (→), red: murine vessels, 
blue: murine cells. Scale bars: 100µm and 25µm (inserts). 
(c) Flow cytometric quantification of ileal homing upon treatment with vedolizumab 
(VZD) and/or α4β1 inhibitor. Left panels: Representative plots. Right panels: Pooled 
statistics (n = 8). 
 
Figure 7: 
Schematic model of α4β7- and α4β1-dependent homing and interference with 
vedolizumab in CD (left side) and UC (right side). In CD, blockade of α4β7 via 
vedolizumab is circumvented by ileal homing via α4β1, which is expressed in 
increased levels. In UC, vedolizumab-induced inhibition of α4β7 leads to significant 
reduction of colonic homing. 
 
Supplementary Figure 1: 
(a) Adhesion of control and CD CD4+ T cells to MAdCAM-1-coated glass slides. 
Upper panels: Representative adhesion assays showing adhered cells from control 
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and CD upon treatment with different concentrations of vedolizumab as indicated. 
Lower panels: Pooled statistics (n = 6-9).  
(b) Flow cytometric quantification of the Foxp3-/Foxp3+ ratio in peripheral blood CD4+ 
T cells from patients receiving vedolizumab therapy visiting our department at week 0 
(visit 1), 2 (visit 2) or 6 (visit 3) of treatment.  
 
Supplementary Figure 2: 
(a) Flow cytometric quantification and statistical analyses of CD62L, PSGL, CXCR3, 
CCR4 and CCR8 expression on peripheral CD4+CD25- Teff cells in controls (n = 7-
15), CD (n = 7-18) and UC (n = 4-10) 
(b) Negative controls for the stainings shown in Fig. 2B. Scale bars: 25µm. 
(c) Representative immunohistochemistry stainings of cryosections from CD patients 
before treatment (BT) with vedolizumab or in the maintenance phase (MP) of therapy 
with natalizumab (NTZ) and vedolizumab (VDZ). Examples of double positive cells 
(i.e. α4β7+) are marked with orange arrows, examples of single NTZ+ cells are 
marked with white arrows. Scale bars: 25µm and 12,5µm (inserts). 
(d) Left panel: Representative flow cytometry of β1 integrin expression on α4β7+ 
CD4+Foxp3- T cells. Right panels: Quantitive flow cytometry indicating the 
percentage of β1+ cells among α4β7+ CD4+Foxp3- T cells in control patients (n = 5), 
CD (n = 5) and UC (n = 2). 
 
Supplementary Figure 3: 
35 
 
 
 
Stratification of the data shown in Fig. 3B according to the localization category of the 
Montreal classification.  
 
Supplementary Video 1: 
Representative 3 minute-clips from dynamic adhesion assays with CD Teff cells in 
control or VCAM-1 coated capillaries and treatment with vedolizumab or natalizumab 
as indicated in fast motion. The blue arrow (left lower corner) indicates the direction 
of the cell stream. Newly adhering cells are marked with white arrows.  
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Supplementary Table 1: Clinical data 
    Control CD UC 
 Blood Number 38 101 32 
 
Age (Ø) 29 38 46 
 
Female % 79 53 44 
 
HBI (Ø) 
 
7.0 (1 – 24) 
 
 
Mayo c.s. (Ø) 
  
2.1 (0 – 6) 
 
Biologicals % 
 
64 * 72 * 
 
Immunosuppressants % 
 
26* 25 * 
   * some patients with both types of medication 
 Gut Number 11 18 7 
 
Age (Ø) 63 41 48 
 
Female % 55 56 43 
  area of active disease % 
 
100 100 
 
histologic severity** 
 
2.5 2.4 
 
Biologicals % 
 
15 14 
 
Immunosuppressants % 
 
45 0 
 
** 1 – low grade, 2 – moderate grade, 3 – high grade 
 
